Goldman Sachs
UNCY icon

Goldman Sachs’s Unicycive Therapeutics UNCY Stock Holding History

Goldman Sachs’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$681K Buy
145,304
+118,211
+436% +$872K ﹤0.01% 5497
2026
Q1 		$178K Buy
+27,093
New +$178K ﹤0.01% 6112
2025
Q4 		– Sell
-45,200
Closed -$197K – 6837
2025
Q3 		$197K Buy
+45,200
New +$197K ﹤0.01% 5958
2025
Q2 		– Sell
-7,348
Closed -$42.2K – 6436
2025
Q1 		$42.2K Sell
7,348
-13
-0.2% -$79 ﹤0.01% 5903
2024
Q4 		$58.5K Sell
7,361
-1,981
-21% -$11K ﹤0.01% 5837
2024
Q3 		$38.1K Buy
9,342
+7
+0.1% +$28 ﹤0.01% 5648
2024
Q2 		$46.8K Buy
9,335
+1
+0% +$10 ﹤0.01% 5475
2024
Q1 		$129K Hold
9,334
– – ﹤0.01% 5200
2023
Q4 		$81K Buy
9,334
+11
+0.1% +$72 ﹤0.01% 5326
2023
Q3 		$80.2K Sell
9,323
-270
-3% -$2.53K ﹤0.01% 5221
2023
Q2 		$123K Buy
+9,593
New +$150K ﹤0.01% 5322

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.94% 1-Year Est. Return

Goldman Sachs's UNCY Position: Q2 2026 in Review

Goldman Sachs increased its Unicycive Therapeutics (UNCY) stake by 436% in Q2 2026, buying an estimated $872K and bringing the position to 145,304 shares worth $681K. The position accounts for ﹤0.01% of the portfolio, ranked #5497.

Goldman Sachs first reported a position in UNCY in Q2 2023 and has held it in 11 quarters since. 73 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Goldman Sachs held 145,304 shares of Unicycive Therapeutics worth $681K as of Q2 2026.
  • Goldman Sachs bought 118,211 Unicycive Therapeutics shares in Q2 2026, an estimated $872K.
  • Unicycive Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5497 holding.
  • Goldman Sachs first reported a position in Unicycive Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • 73 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.